Penn State CRC
University Park, Pennsylvania, 16802, United States
NCT Number: NCT02556749
The purpose of this study is to evaluate the effects of cranberry juice on central and peripheral blood pressure, indices of arterial stiffness, lipid and lipoprotein concentrations and size characteristics, and HDL function. The investigators hypothesize that the bioactive compounds in cranberry juice may elicit beneficial effects on blood pressure and arterial health, as well as LDL-C and HDL function.
Looking for future studies?
Notify Me30 year–65 year
All sexes
Interventional
Not applicable
University Park, Pennsylvania, 16802, United States
The investigators propose to conduct a 2-period randomized, crossover, placebo-controlled study to evaluate the effect of cranberry juice on central and peripheral blood pressure, indices of arterial stiffness, lipid and lipoprotein concentrations and size characteristics, and HDL function. Eligibility requires non-smoking men and women to be 30 to 65 years of age with BMI greater than or equal to 18 and less than or equal to 39, total cholesterol below 273 mg/dL for men and below 284 mg/dL for women, triglycerides below 350 mg/dL, and have systolic blood pressure of 120 to 159 mmHg and/or diastolic blood pressure of 80 to 99 mmHg. Subjects will undergo randomized treatments including 500 mL/d cranberry juice beverage and 500 mL/d of a color and taste matched placebo beverage. The two 8 to 12 week treatment periods will be separated by an 8 week washout.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
16 ounces of 54% cranberry juice cocktail
Color, calorie, and taste matched beverage without cranberry bioactives
Time frame: Change from baseline after 8 week treatments with cranberry and placebo
Aortic (central) blood pressure measured using the SphygmoCor system
Time frame: Change from baseline after 8 week treatments with cranberry and placebo
Peripheral blood pressure measured using the SphygmoCor system
Time frame: Change from baseline after 8 week treatments with cranberry and placebo
Ability to carry out reverse cholesterol transport measured using in vitro assay
Time frame: Change from baseline after 8 week treatments with cranberry and placebo
Augmentation index measured using the SphygmoCor system
Time frame: Change from baseline after 8 week treatments with cranberry and placebo
Pulse wave velocity measured using the SphygmoCor system
Time frame: Change from baseline after 8 week treatments with cranberry and placebo
LDL-C values calculated using the Friedewald equation
Time frame: Change from baseline after 8 week treatments with cranberry and placebo
LDL particle size measured using a Vertical Auto Profile (VAP) Test
Time frame: Change from baseline after 8 week treatments with cranberry and placebo
Total cholesterol values determined by enzymatic procedures
Time frame: Change from baseline after 8 week treatments with cranberry and placebo
Triglyceride values determined using enzymatic procedures
Time frame: Change from baseline after 8 week treatments with cranberry and placebo
HDL-C will be estimated according to the modified heparin-manganese procedure
Time frame: Change from baseline after 8 week treatments with cranberry and placebo
Plasma concentrations of oxLDL will be measured using ELISA kits
Time frame: Change from baseline after 8 week treatments with cranberry and placebo
MDA will be measured using the thiobarbituric acid reactive substances (TBARS) assay
Time frame: Change from baseline after 8 week treatments with cranberry and placebo
hs-CRP will be measured by latex-enhanced immunonephelometry
Time frame: Change from baseline after 8 week treatments with cranberry and placebo
Penn State University
Other
Effects of Cranberry Juice on Cardiovascular Risk Factors in a Placebo-controlled Crossover Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00976742
Cardiovascular Disease Risk Factors, Glucose Metabolism Disorders
College Park, Maryland, United States
View Trial DetailsNCT03354377
Body Weight, Cardiovascular Disease Risk Factors
Columbia, South Carolina, United States
View Trial DetailsNCT03676296
Cardiovascular Disease Risk Factors
Hong Kong, China
View Trial DetailsNCT02235896
Cardiovascular Disease Risk Factors
Rochester, Minnesota, United States
View Trial Details